Proteases and Inhibitors in Breast Tumours
Author Information
Author(s): D. Foucre, C. Bouchet, K. Hacene, N. Pourreau-Schneider, A. Gentile, P.M. Martin, A. Desplaces, J. Oglobin
Primary Institution: Centre Rene Huguenin
Hypothesis
What is the relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant versus benign breast tumours?
Conclusion
Malignant breast tumours have significantly higher levels of cathepsin D, urokinase, and plasminogen activator inhibitors compared to benign tumours.
Supporting Evidence
- Cathepsin D and urokinase levels were found to be 4-fold and 5-fold higher in malignant tumours compared to benign ones.
- PAI-I and PAI-2 levels increased 74-fold and 29-fold respectively in malignant tumours.
- Positive correlations were found between the levels of cathepsin D, urokinase, PAI-I, and PAI-2 in malignant tumours.
Takeaway
This study found that breast cancer tumours have much more of certain proteins that help them spread compared to non-cancerous tumours.
Methodology
The study analyzed the concentrations of cathepsin D, urokinase, and plasminogen activator inhibitors in the cytosols of 130 human mammary tumours using immunoassays.
Limitations
The study only measured global enzyme and inhibitor levels in cytosols, which may not reflect their specific tissue compartment production.
Participant Demographics
130 patients with primary and unilateral breast tumours (43 benign and 87 malignant).
Statistical Information
P-Value
p<0.00001
Statistical Significance
p<0.00001
Want to read the original?
Access the complete publication on the publisher's website